Journal of Solid Tumors最新文献_第4页

Prognostic significance of CXCR4 and mTOR expression in diffuse large B-cell lymphoma patients 弥漫性大b细胞淋巴瘤患者CXCR4和mTOR表达的预后意义

Journal of Solid Tumors Pub Date : 2019-01-15 DOI: 10.5430/JST.V9N1P7

R. Haggag, N. Mostafa, M. Nabil, H. A. Shokralla, N. Sidhom

{"title":"Prognostic significance of CXCR4 and mTOR expression in diffuse large B-cell lymphoma patients","authors":"R. Haggag, N. Mostafa, M. Nabil, H. A. Shokralla, N. Sidhom","doi":"10.5430/JST.V9N1P7","DOIUrl":"https://doi.org/10.5430/JST.V9N1P7","url":null,"abstract":"Background: The aim of this study was to investigate the prognostic role of mammalian target of Rapamycin (mTOR) and C-X-C chemokine receptor type 4 (CXCR4) in diffuse large-B-cell lymphoma (DLBCL) patients.Patients and methods: This retrospective study was collected data from 64 de novo DLBCL patients, who received standardized R-CHOP therapy at two oncology centers. CXCR4 and mTOR expressions were assessed by immunohistochemistry.Results: Out of the 64 DLBCL patients, 40 patients were positive for CXCR4 (62.5%) and 35 patients for mTOR (54.7%) expressions. CXCR4 expression was positively correlated with mTOR expression (r = 0.7; p < .001). While mTOR expression was significantly associated with high lactate dehydrogenase level (p = .03) and number of extranodal sites one or more (p =.02), CXCR4 expression was significantly associated with high IPI score (p < .001) and ECOG PS (p = .005). Furthermore, theexpression levels of mTOR and CXCR4 were significantly associated with older ages and poor response to treatment (p = .04, <.001 and .04, .03, respectively). After a median Follow up of 22 months, mean ± SD overall survival (OS) was 65.391 ± 4.705. Kaplan–Meier analysis showed that patients positive for mTOR and CXCR4 expression had shorter DFS (p = .01 & .02) and OS (p = .02 & .04). Multivariate analysis showed that CXCR4 and mTOR positivity is an independent prognostic factor for significantly poorer DFS (p = .03, and .02 respectively) but not for OS (p = .09 and .08 respectively) in the DLBCL pateints.Conclusion: Our results indicate that the expression of CXCR4 and mTOR may be poor prognostic biomarkers in DLBCL.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"46 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76799708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letrozole and anastrozole in early breast cancer postmenopausal patients in oncology department at Suez Canal University Hospital 来曲唑与阿那曲唑在苏伊士运河大学医院肿瘤科绝经后早期乳腺癌患者中的应用

Journal of Solid Tumors Pub Date : 2019-01-15 DOI: 10.5430/JST.V9N1P12

M. Montasser, Ihab M.A. Hassanin, Soheir E. Abdelmohsen, M. Zamzam

{"title":"Letrozole and anastrozole in early breast cancer postmenopausal patients in oncology department at Suez Canal University Hospital","authors":"M. Montasser, Ihab M.A. Hassanin, Soheir E. Abdelmohsen, M. Zamzam","doi":"10.5430/JST.V9N1P12","DOIUrl":"https://doi.org/10.5430/JST.V9N1P12","url":null,"abstract":"Background: There are limited data in the literature comparing the efficacy of aromatase inhibitors in postmenopausal hormonal receptor positive early breast cancer patients.Aim of study: To compare the efficacy of letrozole and anastrozole in hormone-receptor positive postmenopausal breast cancer patients.Methods: A retrospective study with a mean follow-up period of 64 months (about 5 years) for 74 files of early invasive postmenopausal breast cancer hormonal receptor positive patients; 39 received letrozole and 35 received anastrozole, considering TTP as primary end point, and OS as second end points.Results: Letrozole is not superior to anastrozole during the first 55 months of treatment (80% PFS at 5th year), and 80% OS benefit at 6th year. Overweight patients had better (90% PFS at 5th year) than obese patients (60% PFS at 5th year).Conclusion: Letrozole is not superior to anastrozole in efficacy in early invasive hormonal receptor positive breast cancer postmenopausal patients during the first 5 years of treatment; however, Letrozole 2nd line after tamoxifen is superior to anastrozole 2nd line after tamoxifen in treating obese patients with early invasive hormone receptor positive breast cancer.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78087238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Actinic keratosis prevention – A double-blind, half-face interventional study with a topical treatment 光化性角化病预防-一项局部治疗的双盲半面部介入研究

Journal of Solid Tumors Pub Date : 2018-11-28 DOI: 10.5430/JST.V9N1P1

E. Sorbellini, B. Marzani, D. Pinto, F. Rinaldi

{"title":"Actinic keratosis prevention – A double-blind, half-face interventional study with a topical treatment","authors":"E. Sorbellini, B. Marzani, D. Pinto, F. Rinaldi","doi":"10.5430/JST.V9N1P1","DOIUrl":"https://doi.org/10.5430/JST.V9N1P1","url":null,"abstract":"Actinic keratosis (AK) is a chronic and recurrent disease and in this double-blind, half face, placebo controlled study we attempt to examine the efficacy of a topical treatment containing 2,4,6-octatrienoic acid and anthraquinone knipholone for the prevention of new AK lesion formations. New lesion onset was detected with methyl-5-aminolevulinic acid and Wood’s lamp after 6 months of treatment (T1) and 12 months after treatment end (T2). Absence of new lesion at T1, was 86.11% in active treatment side while 77.78% in placebo side. At T2 the percentage was higher in skin treated with active product (83.33% of subjects) compared to placebo (63.89% of subjects).Taking into consideration the number of new lesions during the study period, at T1 the new AK lesions were not statistically significantly influenced by the treatments, while at T2, AK lesions were detected in 30.55% of placebo-treated area while in the contralateral part the lesions were 13.89%. The reduction induced by active treatment was statistically significant.The product containing 2,4,6-octatrienoicienoic acid and anthraquinone knipholone is effective in reducing new AK lesion formation in subjects with a history of AKs. ","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80493229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hepatic resection for two giant hepatocellular carcinoma after oral direct-acting antiviral therapy: Is there a relationship? 口服直接抗病毒治疗后两例巨大肝癌肝切除术:是否有关系?

Journal of Solid Tumors Pub Date : 2018-09-28 DOI: 10.5430/JST.V8N2P32

M. Wahab, A. Shehta, M. Ali

{"title":"Hepatic resection for two giant hepatocellular carcinoma after oral direct-acting antiviral therapy: Is there a relationship?","authors":"M. Wahab, A. Shehta, M. Ali","doi":"10.5430/JST.V8N2P32","DOIUrl":"https://doi.org/10.5430/JST.V8N2P32","url":null,"abstract":"Introduction: Direct-acting antiviral drugs have been recently introduced for management of chronic hepatitis C virus (HCV) patients. Those medications have achieved a dramatic improvement of sustained virologic response (SVR) reaching almost 90%. However, reports regarding the increased risk of occurrence or recurrence of hepatocellular carcinoma (HCC) in chronic HCV patients who achieved SVR after direct-acting antiviral drugs are controversial.Methods: We report two cases of giant HCCs complicating chronic HCV infection after direct-acting antiviral drugs-based therapies and were managed by major hepatic resection.Results: Two male patients with chronic HCV infection received several regimens oral direct acting antiviral drugs with a SVR for 3 and 6 months, respectively. They complained of progressive right hypochondrial pain and abdominal enlargement. Two large HCCs were diagnosed (16.2 cm * 17.6 cm * 16.9 cm, and 18 cm * 13 cm * 16.5 cm in dimensions) with markedly elevated serum alpha feto-protein (36,000 and 7,000 ng/ml, respectively). Due to the presence of adequate residual liver volume, the decision was to proceed for surgical resection. Central hepatectomy and extended right hemi-hepatectomy were performed, respectively. Patients had smooth postoperative course and were discharged after 10 and 9 days, respectively.Conclusion: The relationship between direct-acting antiviral drugs and HCC is controversial. Those cases add support to the accumulating literature suggesting the relationship of HCC development in chronic HCV patients receiving direct-acting antiviral drugs. Further prospective studies with adequate long term follow up are needed to prove or disprove this relationship.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"14 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84188398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

An algorithm to evaluate the efficacy of detecting somatic mutations 一种评估体细胞突变检测效能的算法

Journal of Solid Tumors Pub Date : 2018-08-15 DOI: 10.5430/jst.v8n2p25

T. Moorthy

{"title":"An algorithm to evaluate the efficacy of detecting somatic mutations","authors":"T. Moorthy","doi":"10.5430/jst.v8n2p25","DOIUrl":"https://doi.org/10.5430/jst.v8n2p25","url":null,"abstract":"Detection of somatic mutations from late stage solid tumors is a critical part of cancer treatment. Although tumor content is used as a convenient parameter to measure efficacy of detection, it fails to include two basic factors: the lower limit of detection (LLOD), and the ratio of the mutant and wild type allele frequencies. Recently, the detection of somatic mutations has expanded to liquid biopsy, early stages of cancer and population screening, which all generally carry lower copy numbers of somatic mutations compared to late stage tumors. With the growing importance of these mutations for targeted chemotherapy and other clinical applications, there is a need re-evaluate the efficacy of detection of somatic mutations. Hence, a new algorithm, Detection Index (DI), is proposed to standardize the efficacy of all molecular methods and is applicable to all types of clinical samples. Detection Index (DI) is based on two basic determinants: lower limit of detection of the mutant allele, and the ratio of the copies of the mutant allele to that of the wild-type. The benefits of DI include (a) standardization of methods detecting somatic mutations so that laboratory reports will have a uniform interpretation related to clinical picture, and (b) the flexibility to use appropriate amounts of DNA and assay conditions to achieve desired DI. ","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"48 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78275600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Prognostic value of platelet to lymphocyte ratio in patients with non-small cell lung cancer 血小板与淋巴细胞比值在非小细胞肺癌患者中的预后价值

Journal of Solid Tumors Pub Date : 2018-07-01 DOI: 10.5430/JST.V9N1P8

M. Elkady, G. Refaat, Z. El-Sayed, Kyrillus Farag

{"title":"Prognostic value of platelet to lymphocyte ratio in patients with non-small cell lung cancer","authors":"M. Elkady, G. Refaat, Z. El-Sayed, Kyrillus Farag","doi":"10.5430/JST.V9N1P8","DOIUrl":"https://doi.org/10.5430/JST.V9N1P8","url":null,"abstract":"Background: The prognostic value of Platelet-to-lymphocyte ratio (PLR) in patients with non-small-cell lung cancer (NSCLC) is still indistinct. We conducted this study to assess the prognostic significance of pretreatment PLR in patients with unresectable NSCLC.Aim of the Work: To assess the prognostic significance of pre-treatment PLR in patients with NSCLC.Material and Methods: We retrospectively reviewed 130 patients treated for NSCLC with definitive/palliative chemotherapy and/or radiotherapy in Ain-Shams Universit hospital, Clinical Oncology department between January 2014 and December 2016. Pre-treatment CBC was available for the 130 patients to calculate PLR by dividing the absolute platelet count by the absolute lymphocytic count.Results: Out of 130 patients with available pre-treatment complete blood picture, population age ranged from 23 to 87 years. Male to female ratio was 4.8:1. Adenocarcinoma presents 51% of cases. Unresectable stage II and stage III present 2% and 27% respectively, while Stage IV presents 69%. Using a cut-off value of 150, a statistically significant correlation between baseline PLR > 150 and presence of distant metastases was found (p = .043); with a trend towards less advanced stage disease among group of patients with baseline PLR < 150 (p = .064). High PLR > 150 was significantly associated with poor overall survival (OS) (median OS: 10.33 months; 95% CI: 6.23-14.42, compared to patients with PLR < 150; (median OS: 24.63 months, 95% CI:11.5-37.76, p = .008), but not PFS. In multivariate analysis, PLR < 150 was an independent good prognostic factor for OS; (HR = 0.549; 95% CI: 0.314-0.958; p = .035).Conclusion: High PLR is associated with poor OS in patients with unresectable NSCLC.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"89 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85605093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imaging pattern and histological features of Gorham-Stout Disease of the radius 桡骨Gorham-Stout病的影像学特征及组织学特征

Journal of Solid Tumors Pub Date : 2018-06-20 DOI: 10.5430/JST.V8N2P20

Clémence Bruyère, V. Garibotto, A. Rougemont, S. Boudabbous

引用次数: 1

Central nervous system penetration and efficacy of targeted therapies used in non-small cell lung cancer and melanoma with brain metastases 中枢神经系统的渗透和靶向治疗用于非小细胞肺癌和脑转移黑色素瘤的疗效

Journal of Solid Tumors Pub Date : 2018-05-03 DOI: 10.5430/JST.V8N2P13

S. Khalid, Aariez Khalid, A. Haddad, T. Spiro, H. Daw

引用次数: 0

Extra-articular osteochondromatosis: A collection of four clinical cases of different localization 关节外骨软骨瘤病:收集4例不同定位的临床病例

Journal of Solid Tumors Pub Date : 2018-04-24 DOI: 10.5430/JST.V8N2P1

A. Caruso, R. Macchia, S. Boudabbous

引用次数: 0

Cytological diagnosis of metastatic melanoma presenting as an isolated pleural effusion: A case report 表现为孤立性胸腔积液的转移性黑色素瘤的细胞学诊断:1例报告

Journal of Solid Tumors Pub Date : 2018-04-24 DOI: 10.5430/JST.V8N2P7

K. Kosmas, Anna Tsonou, G. Mitropoulou, Anastasia Mandilara, O. Papadopoulou, Eufrosyni Salemi

{"title":"Cytological diagnosis of metastatic melanoma presenting as an isolated pleural effusion: A case report","authors":"K. Kosmas, Anna Tsonou, G. Mitropoulou, Anastasia Mandilara, O. Papadopoulou, Eufrosyni Salemi","doi":"10.5430/JST.V8N2P7","DOIUrl":"https://doi.org/10.5430/JST.V8N2P7","url":null,"abstract":"Malignant melanoma (MM) is a malignant melanocytic neoplasm that occurs mainly in the skin but it can also involve any tissue. It has the capacity to metastasize widely and quickly to various sites without any intermediate stops, sometimes many years after treatment of the primary tumor. It is almost impossible to predict which organ system will be invaded by melanoma from a given primary site. We report the cytomorphologic and immunocytochemical findings of a male patient with isolated pleural metastasis of MM without pulmonary parenchymal metastatic involvement after 10 years of progression-free survival. Pleural fluid cytology revealed epithelioid cells of variable sizes and configuration isolated or in clusters with abnormal hyperchromatic nuclei, irregularly-shaped nucleoli, abundant eosinophilic cytoplasm, multinucleated giant cells, intranuclear cytoplamic inclusions as well as many cytoplasmic melanin pigmented tumor cells. Immunocytochemical markers for melanoma HMB-45 and S-100 were positive. Metastasis of MM to pleural fluid is rare and diagnosing the disease by cytology is challenging and requires medical expertise as well as knowledge of clinical context and immunocytochemical staining evaluation.","PeriodicalId":17174,"journal":{"name":"Journal of Solid Tumors","volume":"29 1","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2018-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73599175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0